CN1104897C - 作为3-羟基-3-甲基戊二酰基CoA(HMG-CoA)还原酶抑制剂的橙皮苷和橙皮素 - Google Patents
作为3-羟基-3-甲基戊二酰基CoA(HMG-CoA)还原酶抑制剂的橙皮苷和橙皮素 Download PDFInfo
- Publication number
- CN1104897C CN1104897C CN97198803A CN97198803A CN1104897C CN 1104897 C CN1104897 C CN 1104897C CN 97198803 A CN97198803 A CN 97198803A CN 97198803 A CN97198803 A CN 97198803A CN 1104897 C CN1104897 C CN 1104897C
- Authority
- CN
- China
- Prior art keywords
- hesperidin
- coa
- hmg
- hesperetin
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 title claims description 64
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 title claims description 40
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 title claims description 37
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 title claims description 37
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 title claims description 37
- 229940025878 hesperidin Drugs 0.000 title claims description 37
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 title claims description 37
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 title claims description 37
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 title claims description 30
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 title claims description 27
- 229960001587 hesperetin Drugs 0.000 title claims description 27
- 235000010209 hesperetin Nutrition 0.000 title claims description 27
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 title claims description 27
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 title abstract 6
- 229940123934 Reductase inhibitor Drugs 0.000 title description 2
- 230000000694 effects Effects 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 102000004316 Oxidoreductases Human genes 0.000 claims abstract description 7
- 108090000854 Oxidoreductases Proteins 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 235000013361 beverage Nutrition 0.000 claims abstract 2
- -1 3-hydroxy-3-methyl glutaryl Chemical group 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000003628 erosive effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 abstract 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 abstract 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 abstract 2
- 229940117954 naringenin Drugs 0.000 abstract 2
- 235000007625 naringenin Nutrition 0.000 abstract 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 abstract 2
- 229930019673 naringin Natural products 0.000 abstract 2
- 229940052490 naringin Drugs 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 16
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 230000037396 body weight Effects 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 241000053227 Themus Species 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003098 cholesteric effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- BZFBDUQOBQHBSZ-DLCQERRASA-N (3s,8r,9s,10r,13s,14s,17s)-17-[3-(dimethylamino)propyl-methylamino]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol;dihydrochloride Chemical compound Cl.Cl.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](N(C)CCCN(C)C)[C@@]1(C)CC2 BZFBDUQOBQHBSZ-DLCQERRASA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- RPERJPYDELTDMR-UHFFFAOYSA-K 2-hydroxyethyl(trimethyl)azanium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound C[N+](C)(C)CCO.C[N+](C)(C)CCO.C[N+](C)(C)CCO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O RPERJPYDELTDMR-UHFFFAOYSA-K 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003257 choline citrate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108091006091 regulatory enzymes Proteins 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Obesity (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种抑制哺乳动物的3-羟基-3-甲基戊二酰基CoA(HMG-CoA)还原酶活性的药物组合物,包括有效量的作为活性组分的橙皮苷或橙皮素和药物学上可接受的载体,以及抑制哺乳动物的3-羟基-3-甲基戊二酰基CoA(HMG-CoA)还原酶活性的食品或饮料组合物,包括有效量的橙皮苷或橙皮素。
Description
发明领域
本发明涉及一种抑制哺乳动物的3-羟基-3-甲基戊二酰基CoA(HMG-CoA)还原酶活性的药物组合物,该组合物包括作为活性组分的有效量的橙皮苷或橙皮素以及药物上可接受的载体,此外,还涉及包括有效量的橙皮苷或橙皮素的抑制HMG-CoA还原酶活性的食品或饮料组合物。
发明背景
近年来,冠状心循环疾病,如动脉粥样硬化和血胆甾醇过多已上升成为死亡的主要原因。据报道,血浆中胆甾醇浓度的提高能引起脂肪、巨噬细胞和泡沫细胞沉积在血管上,这种沉积导致形成斑,继而导致动脉粥样硬化(Ross,R.,
Nature,
362,801-809(1993))。降低血浆中胆甾醇浓度的一种方法是营养疗法,减少撮入胆甾醇和脂肪。另一种方法是降低肝脏中胆甾醇的生物合成速率。据报道,血胆甾醇过多可以通过抑制HMG-CoA还原酶(它是合成羟基戊酸的媒介,生物合成甾醇或类异戊二烯的是中间体)来降低胆甾醇生物合成速度有效地治疗(
Cardiovascular Pharmacology,William W.Parmley and Kanu ChatterjeeEd.,Wolfe Publishing,pages 8.6-8.7,1994)。
因此,人们做了很多工作,主要是开发抑制HMG-CoA还原酶的药物;其结果是可以从市场上买到由
Penicillium sp.和
Aspergillus sp.衍生的各种化合物。特别是由美国Merck Co.开发的Lovastatin和Simvastatin以及日本Sankyo Co.开发的Pravastatin已经商业化(C.D.R.Dunn,
Stroke:Trends,Treatment and Markets(中风:趋势、治疗和市场),SCRIPT Report,PJB Publications Ltd.,1995)。然而,药物是非常昂贵的,长期服用会产生副作用,肝脏中肌酸激酶增加。所以,还需要开发一种便宜的无毒性HMG-CoA还原酶抑制剂。
橙皮苷和橙皮苷的糖苷配基、橙皮素是在柠檬、柚子、橘子和橙子(
Citrus sinensis)中发现的类黄酮,它们具有如下结构(Horowitz,Gentili,Tetrahedron,19,773(1943))。橙皮苷橙皮素
橙皮苷已用于防止和治疗大脑贫血、视网膜出血和表紫斑(pelioma),但是没有报道过橙皮苷或橙皮素对HMG-CoA还原酶的抑制活性。
发明概述
本发明的一个目的是提供一种抑制哺乳动物的HMG-CoA还原酶活性的药物组合物。
本发明的另一目的是提供一种抑制哺乳动物的HMG-CoA还原酶活性的食品或饮料组合物。
在本发明的一方面,提供了一种抑制哺乳动物的3-羟基-3-甲基戊酰基CoA(HMG-CoA)还原酶活性的药物组合物,它包括作为活性组分的有效量的橙皮苷或橙皮素,以及药物上可接受的载体。发明详细描述
本发明提供一种抑制HMG-CoA还原酶活性的药物组合物,包括作为活性组分的橙皮苷或橙皮素,以及药物上可接受的赋形剂、载体和稀释剂。
橙皮苷和橙皮素可以从柑桔属的皮中提取,也可以按Zemplen,Bognar,
Ber.,
75,1043(1943)和Seka,Prosche,
Monatsh.,
69,284(1936)上公开的方法合成。进一步说,橙皮素可以通过橙皮苷水解来制备。
橙皮苷或橙皮素在0.5mg/Kg体重/天或更高的剂量下对HMG-CoA还原酶具有抑制作用,随用量的增加抑制作用也升高。
此外,不管它们的潜在功效,在使用小鼠进行的试验中,橙皮苷和橙皮素表现出低的毒性或促有丝分裂性(mitogenicity)。具体地说,当小鼠口服1,000mg橙皮苷/Kg体重的剂量时,未表现出毒性,这一量相当于体重为50Kg的人口服50-100g橙皮苷/Kg体重。进一步说,橙皮苷和橙皮素对肝脏功能没有副作用。
药物制剂可以按任何常规方法通过组合物来制备。在制剂的制备过程中,活性组分优选与载体混合或用载体稀释,或包封在载体中,载体可以是胶囊、球囊(sachet)或其它容器的形式。当载体作为稀释剂时,可以是固体、半固体或液体材料,起活性组分载体(vehicle)、赋形剂或介质的作用。所以,制剂可以是药片、药丸、粉剂、球囊、酏剂、分散液、乳化液、溶液、糖浆、气溶胶、软或硬凝胶胶囊、无菌注射液、无菌包装粉末等。
合适的载体、赋形剂和稀释剂的例子乳糖、葡萄糖、蔗糖、山梨糖醇、甘露糖醇、淀粉、阿拉伯树胶、藻酸盐、凝胶、磷酸钙、硅酸钙、纤维素、甲基纤维素、微晶纤维素、聚乙烯吡咯烷酮、水、羟基苯甲酸甲酯、羟基苯甲酸丙酯、滑石、硬脂酯镁和矿物油。此外,制剂中可以包括填料、抗絮凝剂、润滑剂、增湿剂、调味剂、乳化剂、防腐剂等。本发明的组合物可以通过任何本领域内已知的方法制成在哺乳动物施服用后提供快速、持久或缓释活性组分的形式。
本发明的药物制剂可以通过种种方式施用,包括口服、经皮、皮下、静脉和肌内引入。对于人,橙皮苷或橙皮素的日服用量典型地为0.5-300mg/Kg体重/天,优选5-30mg/Kg体重/天,可以一次服用,也可以分几次服用。然而,应当理解,活性组分的实际服用量应根据不同因素确定,包括要治疗的情况、所选择的给药途径、各个病人年龄、性别、体重,以及病人症状的严重程度;因此,上述剂量的不应以任何方式限制本发明。
此外,橙皮苷和橙皮素可以引入到食品或饮料中以抑制HMG-CoA还原酶的活性。因此,本发明还提供了一种抑制HMG-CoA还原酶活性的食品或饮料组合物,包括有效量的橙皮苷或橙皮素。
正如上面所述,橙皮苷或橙皮素可以作为有效的、无毒药剂使用,以抑制HMG-CoA还原酶的活性。
以下实施例用于进一步说明本发明,但不是限定本发明的范围。
另外,除特别声明外,在下面给出的百分数,对于固体混合物中的固体、液体中的液体、液体中的固体分别是以重量/重量,体积/体积,重量/体积为基础的,所有反应都在室温下进行。实施例1:给动物施用橙皮苷和橙皮素
体重为约90-110克的24只四周龄的Sprague-Dawley鼠(Taihanlaboratory animal center,Korea)平均随机分成三个食疗组。三组小鼠喂给不同的高胆甾醇食物,即AIN-76实验动物食物(ICN Biochemicals,Cleveland,OH,USA),分别含有1%胆甾醇(对照组),1%胆甾醇和0.1%橙皮苷(橙皮苷组),1%胆甾醇和0.1%橙皮素(橙皮素组)。喂给三组小鼠的食物的组成列于表I。
表I
*1:从TEKLAD Premier Co.(Madison,WI,USA)购得*2:从Sigma Chemical Company(St.Louis,Mo,USA)购得
食谱组分 | 对照组 | 橙皮苷组 | 橙皮素组 |
酪蛋白 | 20 | 20 | 20 |
D,L-蛋氨酸 | 0.3 | 0.3 | 0.3 |
玉米淀粉 | 15 | 15 | 15 |
蔗糖 | 49 | 48.9 | 48.9 |
纤维素粉*1 | 5 | 5 | 5 |
矿物混合物*1 | 3.5 | 3.5 | 3.5 |
维生素混合物*1 | 1 | 1 | 1 |
柠檬酸胆碱 | 0.2 | 0.2 | 0.2 |
玉米油 | 5 | 5 | 5 |
胆甾醇 | 1 | 1 | 1 |
橙皮苷*2 | 0.1 | ||
橙皮素*2 | 0.1 | ||
总量 | 100 | 100 | 100 |
鼠按特定食物和水自由进食六周,每天记录撮取食量,每七天称重,然后记录分析。所有老鼠都表现出正常的生长速度,从食物撮取量和体重的增长上三个组中没有发现明显的差异。实施例2:确定血浆内的总胆甾醇、HDL-胆甾醇和中性脂的含量
给鼠施用橙皮苷或橙皮素对血浆中胆甾醇和中性脂含量的效果按以下方法确定。
从三个食疗组的鼠采取血样,使用含有硫酸葡萄糖酯的HDL-胆甾醇试剂(Sigma Chemical Co.,Cat.No.352-3)分离血浆HDL组分。总胆甾醇和HDL-胆甾醇浓度用Sigma Diagnostic Kit Cat.No.352-100(SigmaChemical Co.,USA)(Allain等,
Clin.Chem.,20,470-475(1974))确定。中性脂的浓度用Sigma Diagnostic Kit Cat.No.339-50(Bucolo,G.and David,H.,
Clin.Chem.,19,476-482(1973))确定。结果列于表II,与对照组比较,喂给橙皮苷的一组鼠中总血浆胆甾醇浓度降低了11%,在喂给橙皮素的一组鼠中降低了15%。
为了确定喂给鼠的橙皮苷和橙皮素对HMG-CoA还原酶—肝脏中合成胆甾醇的调节酶—的活性影响,从肝脏组织中分离微粒体作为酶源。
首先,用断头法杀死三组老鼠,切下肝脏,立即放入冰-冷的均化介质中(50mM K2PO4(pH7.0),0.2M蔗糖,2mM二硫苏糖醇(DTT))。在均化介质(2ml介质/g肝脏)中,用Waring搅拌器搅拌15秒钟将肝脏均化(在Potter-Elvehjem型玻璃均化器中用马达驱动的四氟乙烯杵冲击三次)。均浆在15,000xg下离心10分钟,获得的上清液在100,000xg下离心75分钟,获得微粒体粒状沉淀,然后再分散到含有50mM EDTA的均化介质中,并在100,000xg下离心60分钟。含有微粒体的上清液作为酶源。(步骤2)HMG-CoA还原酶测定
按照Shapiro等人的方法用[14C]HMG-CoA确定HMG-CoA还原酶的活性(
Biochemica et Biophysica Acta,370,369-377(1974))如下。
在步骤1中获得的含有微粒体的上清液中酶在37℃下活化30分钟。向反应管中加入20μl的HMG-CoA还原酶测定缓冲液(0.25M K2PO4(pH7.0),8.75mM EDTA,25mM DTT,0.45M KCl和0.25mg/ml BSA),5μl的50mM NADPH,5μl的[14C]HMG-CoA(0.05μCi/管,最终浓度为120μM),以及10μl的活化微粒体酶(0.03-0.04mg),混合物在37℃下培养30分钟。通过向该混合物中加入10μl的6M HCl,反应被终止,混合物在37℃培养15分钟,使产物(甲羟戊酸)完全内酯化。在10,000xg下离心1分钟除去沉淀,上清液涂布到硅胶60G TLC板上(Altech,Inc.,Newark,USA),然后,用苯∶丙酮展开(1∶1,v/v)。用一次性盖板刮掉Rf值为0.65-0.75的区域,并用1450 Microbeta液体闪烁计数器(Wallacoy,Finland)测定其放射性。以每分钟内每mg蛋白质合成3,5-二羟基-3-甲基戊酸的皮摩尔数(pmol/min/mg蛋白质)计算酶的活性。所得结果列于表III。
表III
组 | 对比组 | 橙皮苷组 | 橙皮素组 |
HMG-CoA还原酶活性(皮摩尔/min/mg蛋白质) | 147±12.5 | 112.1±12.8 | 118.5±14.3 |
从表III可以看出,对照组的鼠具有相对高的HMG-CoA还原酶的活性,而喂给橙皮苷组和橙皮素组的鼠中观察到的HMG-CoA还原酶的活性分别比对照组低24%和19%。实施例4:口服橙皮苷的毒性
7-8周龄的无特定病原体的ICR雌性小鼠(8只),每只体重约25-29g,以及雄性小鼠(8只),每只体重约34-38g,在22±1℃的温度、55±5%的湿度和12L/12D光周期下饲养,饲料(Cheiljedang Co.小鼠及大鼠饲料)和水经灭菌后喂给小鼠。
橙皮苷溶解在0.5%的吐温80中,其浓度为100mg/ml,小鼠口服该溶液,其量为0.2ml/20g小鼠体重。服用溶液后,对老鼠进行为期10天的观察,观察其副作用或死亡:服用后1、4、8、12小时观察一次,以后是每隔12小时观察一次。每天记录小鼠的体重变化以考察橙皮苷的作用。在第10天,杀掉小鼠以肉眼观察其内脏。
在第10天,所有的小鼠都存活,表明剂量为1,000mg/kg的橙皮苷对小鼠没有毒性。尸检表明,在10天的试验中,小鼠没有任何病理异常,体重也没有减少。因此,可以推断,口服橙皮苷对人体没有毒性。
以下配方实施例仅用于说明本发明,而不以任何方式限定本发明的范围。配方实施例
按以下配方制备硬凝胶胶囊:
量(mg/胶囊)活性组分(橙皮苷) 20淀粉,干 160硬脂酸镁 20总量 200mg
本发明已根据具体实施方案进行了描述,应当认识到,本领域内的技术人员可以作出各种改进和变化,但都在本发明的权利要求书限定的范围内。
Claims (2)
1.橙皮苷或橙皮素在制备用于抑制哺乳动物的3-羟基-3-甲基戊二酰基CoA还原酶活性的组合物中的用途。
2.如权利要求1所述的用途,其中所述组合物选自药物组合物、食品组合物和饮料组合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1996/45735 | 1996-10-14 | ||
KR1019960045735A KR100213895B1 (ko) | 1996-10-14 | 1996-10-14 | 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1233175A CN1233175A (zh) | 1999-10-27 |
CN1104897C true CN1104897C (zh) | 2003-04-09 |
Family
ID=19477355
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97198801A Pending CN1233182A (zh) | 1996-10-14 | 1997-10-13 | 作为3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂的桔皮提取物 |
CN97198802A Expired - Fee Related CN1106840C (zh) | 1996-10-14 | 1997-10-13 | 作为3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂的柚皮苷和柚苷配基 |
CN97198803A Expired - Fee Related CN1104897C (zh) | 1996-10-14 | 1997-10-13 | 作为3-羟基-3-甲基戊二酰基CoA(HMG-CoA)还原酶抑制剂的橙皮苷和橙皮素 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97198801A Pending CN1233182A (zh) | 1996-10-14 | 1997-10-13 | 作为3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂的桔皮提取物 |
CN97198802A Expired - Fee Related CN1106840C (zh) | 1996-10-14 | 1997-10-13 | 作为3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂的柚皮苷和柚苷配基 |
Country Status (10)
Country | Link |
---|---|
US (3) | US5792461A (zh) |
EP (3) | EP1014968B1 (zh) |
JP (3) | JP3340135B2 (zh) |
KR (3) | KR100213895B1 (zh) |
CN (3) | CN1233182A (zh) |
CA (3) | CA2268439C (zh) |
DE (3) | DE69718030T2 (zh) |
HK (2) | HK1022104A1 (zh) |
RU (2) | RU2174392C2 (zh) |
WO (3) | WO1998016239A1 (zh) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239114B1 (en) * | 1997-09-26 | 2001-05-29 | Kgk Synergize | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
CN1124134C (zh) * | 1997-10-28 | 2003-10-15 | 韩国科学技术研究院 | 柚苷和柚苷配基作为肝病的预防或治疗剂的应用 |
WO2000023073A1 (en) * | 1998-10-20 | 2000-04-27 | Korea Institute Of Science And Technology | Bioflavonoids as plasma high density lipoprotein level increasing agent |
JP2002535410A (ja) * | 1999-01-27 | 2002-10-22 | ザィエリンスキ,ラブラトリー | 高められたバイオアベイラビリティーを有するヘスペレチンプロフォーム |
US6123968A (en) * | 1999-03-23 | 2000-09-26 | Mendez; Alejandro | Composition for extending shelf life for fresh fruits and vegetables without the use of refrigeration |
US6797300B2 (en) * | 1999-03-23 | 2004-09-28 | Alejandro Mendez | Composition for preserving fresh cut flowers, fresh fruits and vegetables without the use of refrigeration |
US20050037116A1 (en) * | 1999-03-23 | 2005-02-17 | Alejandro Mendez | Synthetic solution for preserving fresh flowers, fruits, and vegetables without the use of refrigeration, and method of producing same |
KR100314668B1 (ko) * | 1999-05-26 | 2001-11-17 | 은종방 | 감귤과피에서 펙틴과 헤스페리딘의 연속추출방법 |
US6426362B1 (en) * | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
US20020006953A1 (en) * | 1999-11-05 | 2002-01-17 | Carla R. McGill | Modification of cholesterol concentrations with citus phytochemicals |
WO2002026047A1 (en) * | 2000-09-25 | 2002-04-04 | Alejandro Mendez | Composition for preserving fruits and vegetables, method of making said composition, and method of using said composition without refrigeration |
AU2001232182A1 (en) * | 2001-01-15 | 2002-07-24 | Kgk Synergize | Compositions and methods for regulating lipoproteins and hypercholesterolmia with limonoids flavonoids and tocotrienols |
DE10122898A1 (de) * | 2001-05-11 | 2002-11-14 | Haarmann & Reimer Gmbh | Verwendung von Hydroxyflavanonen zur Maskierung des bitteren Geschmacks |
US8337914B2 (en) * | 2002-02-27 | 2012-12-25 | Access Business Group International Llc | Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation |
US20030170327A1 (en) * | 2002-03-05 | 2003-09-11 | Dahl Eva Marie | Vitamin and zinc monomethionine compositions |
KR20030082219A (ko) * | 2002-04-17 | 2003-10-22 | 한국생명공학연구원 | 플라바논 에스테르 유도체 및 이를 포함하는 혈중 지질농도 관련 질환의 예방 및 치료용 조성물 |
KR100479736B1 (ko) * | 2002-06-28 | 2005-03-30 | (주)바이오뉴트리젠 | 천연 식물체 유래의 혼합분말 또는 추출물을 포함하는 지방간 예방용 식품 |
FR2841472B1 (fr) * | 2002-06-28 | 2006-02-24 | Agronomique Inst Nat Rech | Composition nutritionnelle ou therapeutique contenant le compose hesperidine ou l'un de ses derives |
US7867525B2 (en) * | 2002-08-14 | 2011-01-11 | Bionutrigen Co., Ltd. | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
US20050080024A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
US20040033480A1 (en) * | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
US20050080021A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders |
JP2005130811A (ja) * | 2003-10-31 | 2005-05-26 | Yutaka Miyauchi | 柑橘類の果皮を原材料とする液状飲用物 |
JP2005137204A (ja) * | 2003-11-04 | 2005-06-02 | Yutaka Miyauchi | 液状飲用物 |
KR100702567B1 (ko) * | 2004-06-09 | 2007-04-02 | 퓨리메드 주식회사 | 심근경색 발작 후 회복을 위한 지각 추출물 및 이를 함유하는 약학적 조성물과 건강 식품 |
JP4745764B2 (ja) * | 2004-09-09 | 2011-08-10 | 花王株式会社 | Ampk活性化剤 |
CN1760363B (zh) * | 2004-10-14 | 2010-04-28 | 蒋继宏 | 杜仲3-羟基-3-甲基戊二酰辅酶a还原酶蛋白编码序列 |
US8093273B2 (en) * | 2004-10-20 | 2012-01-10 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
GB2423928B (en) * | 2004-11-16 | 2008-04-09 | Efflux Technology Inc | Methods and compositions for treating pain |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
EP2368442B1 (en) | 2005-07-27 | 2014-12-17 | Symrise AG | Use of hesperetin for enhancing the sweet taste |
KR101431279B1 (ko) * | 2005-07-29 | 2014-08-20 | 리스버로직스 코퍼레이션 | 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달 |
WO2007150063A2 (en) * | 2006-06-23 | 2007-12-27 | Cargill Incorporated | Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements |
ES2454966T3 (es) * | 2007-02-01 | 2014-04-14 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
JP2009256256A (ja) * | 2008-04-18 | 2009-11-05 | Kyushu Univ | 組成物及び飲食品 |
RU2520098C2 (ru) | 2008-06-26 | 2014-06-20 | Ресверлоджикс Корп. | Способы получения производных хиназолинона |
WO2010079431A2 (en) | 2009-01-08 | 2010-07-15 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
NZ595747A (en) | 2009-03-18 | 2015-06-26 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
KR20190091564A (ko) | 2009-04-22 | 2019-08-06 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
US8323513B2 (en) | 2009-07-28 | 2012-12-04 | Cp Kelco Aps | Dewatering biomass material comprising polysaccharide, method for extracting polysaccharide from biomass material, and dewatered biomass material |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
KR101444698B1 (ko) * | 2010-12-30 | 2014-10-07 | 주식회사 엘지생명과학 | 위장관 운동 장애 질환의 개선, 치료 및 예방용 조성물 |
US9499640B2 (en) | 2011-01-21 | 2016-11-22 | Cp Kelco Aps | Preservation of biomass material comprising polysaccharide and method for extracting polysaccharide from preserved biomass material |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
CN103304610A (zh) * | 2012-12-24 | 2013-09-18 | 李玉山 | 一种甲基橙皮苷的制备工艺 |
EA201591476A1 (ru) | 2013-02-06 | 2016-02-29 | Университет Брандайс | Лечение повреждений днк и митохондриальной дисфункции с применением сока плодов масличной пальмы |
CN103263427A (zh) * | 2013-05-07 | 2013-08-28 | 浙江大学 | 新橙皮苷在制备防治高脂血症药物中的应用 |
US9132117B2 (en) | 2013-06-17 | 2015-09-15 | Kgk Synergize, Inc | Compositions and methods for glycemic control of subjects with impaired fasting glucose |
TWI634886B (zh) * | 2014-08-22 | 2018-09-11 | 財團法人國防教育研究基金會 | Compound composition for liver-free side effects with reduced liver fat for treating symptoms of non-alcoholic fatty liver disease (NAFLD) |
JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
KR102139253B1 (ko) * | 2018-05-04 | 2020-07-29 | (주)노아스 | 시트러스 과피 추출물을 포함하는 카페인에 의한 수면장애 개선용 조성물 |
KR102113583B1 (ko) * | 2019-10-25 | 2020-05-21 | 경희대학교 산학협력단 | 레몬 추출물 및 오렌지 추출물을 포함하는 카페인에 의한 수면장애 개선용 조성물 |
CA3199539A1 (en) * | 2020-11-20 | 2022-05-27 | Costanza Valentina RICCIONI | Composition comprising natural extracts and uses thereof |
CN115896201B (zh) * | 2023-01-09 | 2023-05-26 | 成都欧康医药股份有限公司 | 一种4-甲氧基-3,5`,7`-三羟基黄烷酮的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54154569A (en) * | 1978-05-20 | 1979-12-05 | Lotte Co Ltd | Chewing gum for sports |
WO1994023717A1 (en) * | 1993-04-20 | 1994-10-27 | The Procter & Gamble Company | Methods of using hesperetin for sebum control and treatment of acne |
EP0719554A1 (en) * | 1993-07-09 | 1996-07-03 | Kureha Chemical Industry Co., Ltd. | Chondroprotective flavonoids |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1179019A (en) * | 1967-05-23 | 1970-01-28 | Produits Chimique Soc Et | Polynicotinic Esters of Flavonoids |
US4277464A (en) * | 1975-09-19 | 1981-07-07 | General Foods Corporation | Preventing tooth demineralization using aspartame |
US4497842A (en) * | 1982-01-18 | 1985-02-05 | Ehrlich Joseph R | Beverages obtained from alcoholic treatment of roasted citrus fruit peels |
US4497838A (en) * | 1982-02-17 | 1985-02-05 | Tropicana Products, Inc. | Process for the production of useful products from orange peel |
JPS60214858A (ja) * | 1984-04-09 | 1985-10-28 | Toshio Horiuchi | 血糖改善食品 |
EP0185117A1 (de) * | 1984-12-21 | 1986-06-25 | IPEX Getränke-Herstellungs- und Vertriebsgesellschaft mbH | Getränk |
JPS63104920A (ja) * | 1986-10-21 | 1988-05-10 | Tsumura & Co | アルド−スリダクタ−ゼ阻害剤 |
WO1989005141A1 (en) * | 1987-12-10 | 1989-06-15 | Tsumura Juntendo, Inc. | Anti-retroviral drug |
FR2633182B1 (fr) * | 1988-06-23 | 1993-07-23 | Beljanski Mirko | Composition pharmaceutique anticancereuse et methode d'utilisation de l'invention |
MC2041A1 (fr) * | 1988-06-24 | 1990-05-30 | Johannes Cornelius Str Andries | Agents anti-atherogenic |
US4997658A (en) * | 1988-11-21 | 1991-03-05 | Merck & Co., Inc. | Method for enhancing the lowering of plasma cholesterol levels |
JPH03275625A (ja) * | 1990-03-23 | 1991-12-06 | Nippon Oil & Fats Co Ltd | 制癌剤およびその製造法 |
JPH04295428A (ja) * | 1991-03-22 | 1992-10-20 | Dai Ichi Seiyaku Co Ltd | 抗アレルギー剤 |
JPH04346933A (ja) * | 1991-05-24 | 1992-12-02 | Pokka Corp | 虫歯菌、歯周病原菌増殖阻害剤 |
JP3159509B2 (ja) * | 1992-03-30 | 2001-04-23 | サンスター株式会社 | プロテアーゼ阻害剤 |
WO2000023073A1 (en) * | 1998-10-20 | 2000-04-27 | Korea Institute Of Science And Technology | Bioflavonoids as plasma high density lipoprotein level increasing agent |
DE10152638A1 (de) * | 2001-10-16 | 2003-04-24 | Ralph Peter Hegler | Vorrichtung zur Herstellung von gewellten Kunststoff-Rohren |
-
1996
- 1996-10-14 KR KR1019960045735A patent/KR100213895B1/ko not_active IP Right Cessation
-
1997
- 1997-10-13 JP JP51820898A patent/JP3340135B2/ja not_active Expired - Fee Related
- 1997-10-13 EP EP97944200A patent/EP1014968B1/en not_active Expired - Lifetime
- 1997-10-13 EP EP97944201A patent/EP0930889B1/en not_active Expired - Lifetime
- 1997-10-13 CA CA002268439A patent/CA2268439C/en not_active Expired - Fee Related
- 1997-10-13 CA CA002268437A patent/CA2268437C/en not_active Expired - Fee Related
- 1997-10-13 WO PCT/KR1997/000192 patent/WO1998016239A1/en active IP Right Grant
- 1997-10-13 CN CN97198801A patent/CN1233182A/zh active Pending
- 1997-10-13 EP EP97944199A patent/EP0957911B1/en not_active Expired - Lifetime
- 1997-10-13 CN CN97198802A patent/CN1106840C/zh not_active Expired - Fee Related
- 1997-10-13 DE DE69718030T patent/DE69718030T2/de not_active Expired - Lifetime
- 1997-10-13 DE DE69727707T patent/DE69727707T2/de not_active Expired - Lifetime
- 1997-10-13 CN CN97198803A patent/CN1104897C/zh not_active Expired - Fee Related
- 1997-10-13 DE DE69728064T patent/DE69728064T2/de not_active Expired - Lifetime
- 1997-10-13 JP JP10518207A patent/JP2001502321A/ja not_active Ceased
- 1997-10-13 CA CA002268438A patent/CA2268438C/en not_active Expired - Fee Related
- 1997-10-13 RU RU99109602/14A patent/RU2174392C2/ru not_active IP Right Cessation
- 1997-10-13 WO PCT/KR1997/000191 patent/WO1998016221A1/en active IP Right Grant
- 1997-10-13 RU RU99109690/14A patent/RU2174393C2/ru not_active IP Right Cessation
- 1997-10-13 JP JP10518206A patent/JP2001502320A/ja not_active Ceased
- 1997-10-13 WO PCT/KR1997/000190 patent/WO1998016220A1/en active IP Right Grant
- 1997-10-14 US US08/949,234 patent/US5792461A/en not_active Expired - Lifetime
- 1997-10-14 US US08/949,669 patent/US5763414A/en not_active Expired - Lifetime
- 1997-10-14 US US08/949,791 patent/US5877208A/en not_active Expired - Lifetime
-
1999
- 1999-01-25 KR KR1019990002189A patent/KR100213898B1/ko not_active IP Right Cessation
- 1999-01-25 KR KR1019990002202A patent/KR100213899B1/ko not_active IP Right Cessation
-
2000
- 2000-02-29 HK HK00101265A patent/HK1022104A1/xx not_active IP Right Cessation
- 2000-02-29 HK HK00101266A patent/HK1022105A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54154569A (en) * | 1978-05-20 | 1979-12-05 | Lotte Co Ltd | Chewing gum for sports |
WO1994023717A1 (en) * | 1993-04-20 | 1994-10-27 | The Procter & Gamble Company | Methods of using hesperetin for sebum control and treatment of acne |
EP0719554A1 (en) * | 1993-07-09 | 1996-07-03 | Kureha Chemical Industry Co., Ltd. | Chondroprotective flavonoids |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1104897C (zh) | 作为3-羟基-3-甲基戊二酰基CoA(HMG-CoA)还原酶抑制剂的橙皮苷和橙皮素 | |
US6509372B2 (en) | Method for preventing or treating elevated blood lipid level-related diseases by administering rutin and quercetin | |
US8895079B2 (en) | Combinations of botanical extracts for promoting cardiovascular health | |
CN101516407B (zh) | 改善精氨酸酶水平/活性 | |
WO2009094177A1 (en) | Protopanaxadiol-type ginsenoside compositions and uses thereof | |
CA2344401A1 (en) | Composition containing natural phenolic compounds for preventing or treating elevated blood lipid level-related diseases | |
US10265335B2 (en) | Use of non-digestible oligosaccharides | |
EP1729598B1 (en) | Composition; use of a composition and a method for preventing fat absorption | |
RU2173164C2 (ru) | ЭКСТРАКТ ИЗ КОЖУРЫ ПЛОДОВ ЦИТРУСОВЫХ В КАЧЕСТВЕ ИНГИБИТОРА 3-ГИДРОКСИ-3-МЕТИЛГЛУТАРИЛ-СoА (ГМГ - СoА) -РЕДУКТАЗЫ | |
JP2002121132A (ja) | 発がん抑制剤および発がん抑制方法 | |
JP2002080355A (ja) | 高血圧症予防・治療剤 | |
KR20140124105A (ko) | 페닐부틸산 또는 이의 약학적으로 허용가능한 염을 포함하는 골다공증 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030409 Termination date: 20121013 |